Eli Lilly And Company

This study looks at how a once-weekly drug called retatrutide affects recovery from low blood sugar in people with type 2 diabetes. About 78 adults who manage their diabetes with diet, exercise, and metformin will take either the drug or a placebo for 16 weeks. Researchers will m…

This study compares the long-term effects of tirzepatide, a newer diabetes medication, with standard treatments in 780 adults who were diagnosed with type 2 diabetes within the last 4 years. Participants must be on metformin alone and have moderately high blood sugar levels. The …

This phase 3 study tested whether adding the drug abemaciclib to standard hormone therapy (fulvestrant) helps women with a common type of advanced breast cancer (HR+, HER2-) live longer without their cancer growing. About 669 women took part, receiving either the combination or f…

This study tests whether adding the drug abemaciclib to standard chemotherapy can help people with Ewing's sarcoma whose cancer has returned or not responded to treatment. About 46 children and young adults will take part. The goal is to see if the combination slows tumor growth …

This study tests a once-daily tablet called orforglipron to see if it helps people with obesity or overweight lose weight safely, compared to a placebo. It includes people with and without type 2 diabetes. About 1,200 participants will be assigned to one of two substudies based o…

This study tests a new radioactive drug called [Ac-225]-PSMA-62 in men with prostate cancer that has spread. The drug targets a protein on cancer cells to deliver radiation directly. The goal is to find the safest dose and check for side effects in 142 participants with either ho…

This study tests a new medicine called lebrikizumab, given alone or with a steroid cream, for people with moderate-to-severe eczema (atopic dermatitis). About 300 adults will receive the drug or a placebo for up to 62 weeks. The goal is to see if it safely reduces skin redness, i…

This study tests a drug called lebrikizumab for people with moderate-to-severe hand and foot eczema. About 206 adults and teens will receive either the drug or a placebo for 16 weeks. The goal is to see if the drug clears skin lesions and reduces itching better than a placebo.

This study compares a new weekly injection, retatrutide, to the existing drug semaglutide for adults with type 2 diabetes whose blood sugar is not well controlled by metformin. About 1250 participants will receive one of the two medications for up to 26 months. The main goal is t…

This study tests a once-weekly injection called retatrutide in about 1,946 people with severe obesity (BMI 35 or higher) and heart disease. The goal is to see if it helps with weight loss and improves heart-related health measures over nearly two years. Participants are randomly …

This study tests a once-daily pill called orforglipron to see if it helps people with obesity or overweight lose weight. About 600 adults will take either the pill or a placebo for 18 months. The main goal is to measure how much weight they lose and check for side effects.

This study tests whether the drug baricitinib is safe and effective for children and teenagers with moderate to severe atopic dermatitis (eczema). About 516 participants will receive either baricitinib or a placebo. The goal is to see if the drug can clear skin or reduce eczema s…

This early-stage study tests an oral drug called LOXO-338 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma. Participants must have already received standard treatments. The main goals are to find the safest dose and see if the drug helps control…

This study tests a new drug called eltrekibart in 352 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition. The goal is to find the best dose and dosing schedule to reduce abscesses and inflammation. Participants will receive either eltrekibart o…

This early-phase study tests a new drug called LY4066434 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 750 participants with pancreatic, lung, or co…

This study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug is safe and works against the cancer. About 193 participants will take the drug alone or with oth…

This study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with a specific RET gene change. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and doctors …

This study looks at how well and how safely the drug mirikizumab works over the long term for people with Crohn's disease. About 1,000 adults who completed earlier mirikizumab studies will continue treatment for up to 52 weeks. The goal is to see if the drug can keep the disease …

This phase 3 trial tests whether a once-daily pill called orforglipron can improve sleep apnea in 600 adults with moderate-to-severe sleep apnea who are also obese or overweight. Participants are split into two groups: those who cannot or will not use a CPAP machine, and those wh…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This early-stage study tests a new drug called LY4101174 in people with advanced or metastatic solid tumors that have come back or spread. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The study aims to find a safe dose and see if the drug can sh…

This study tests an experimental drug called remternetug against a placebo in 1400 people with early Alzheimer's who are at risk for worsening memory and thinking problems. The goal is to see if the drug can delay or prevent further decline in daily function and cognition. Partic…

This study tests whether the drug selpercatinib can delay the return of non-small cell lung cancer in people with a specific gene change (RET fusion) after they have had surgery or radiation. About 152 participants with early-stage cancer (IB-IIIA) will receive either selpercatin…

This phase 3 trial tests a once-daily medication called orforglipron in about 487 adults who have both high blood pressure and obesity or overweight. The study measures how well the drug lowers blood pressure and body weight compared to a placebo. Participants take the pill daily…

This early-stage study tests a new drug called LY3295668 erbumine in children whose neuroblastoma has come back or not responded to treatment. The main goal is to see if the drug is safe and to find the right dose. About 71 participants will receive the drug alone or with other c…

This early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…

This Phase 3 study tests a once-daily pill called orforglipron in 487 adults with high blood pressure who are also overweight or have obesity. The main goal is to see if it lowers blood pressure more than a placebo. Researchers will also check for weight loss and other health imp…

This early-stage study tests a new drug called LY3537031 in overweight, obese, and healthy volunteers. The main goal is to check safety and how the body handles the drug. Researchers will also measure changes in body weight and blood sugar. The study involves about 302 people and…

This study tested whether adding the drug abemaciclib to standard care helps people with stage IV lung cancer that has a KRAS mutation live longer. All 453 participants had already tried chemotherapy. Half received abemaciclib plus supportive care, the other half received erlotin…

This study tests different doses of tirzepatide in 414 adults with type 2 diabetes and obesity who are already taking metformin. The main goal is to see how much weight participants lose and how well their blood sugar is controlled over about 89 weeks. Participants are randomly a…

This study looks at whether tirzepatide, a medication already used for diabetes and weight loss, can help slow or improve chronic kidney disease in people with obesity. About 140 participants will take the drug and have MRI scans to measure kidney fat and blood flow over 56 weeks…

This early-stage study tested the safety of a new drug called abemaciclib when combined with various other breast cancer treatments. It involved 198 people whose breast cancer had spread to other parts of the body. The goal was to see if these combinations were safe enough to stu…

This study tests different dosing schedules of the drug donanemab in about 1,175 people with early symptomatic Alzheimer's disease. The goal is to find a regimen that lowers brain amyloid plaques while reducing the risk of a side effect called ARIA-E (brain swelling or small blee…

This early-phase study tests the safety of a new drug called LY3200882 in 223 adults with solid tumors. Researchers aim to find a safe dose and check if the drug can shrink tumors. The study is not yet recruiting and is actively ongoing.

This study tested an oral drug called selpercatinib in 857 people with advanced solid tumors that have a specific genetic change (RET). The goal was to find the best dose and see if the drug can shrink tumors. Participants had cancers like lung, thyroid, or colon that had stopped…

This study tests a new drug called LY3541860 in 35 adults with moderate-to-severe rheumatoid arthritis who did not get better with at least one other biologic or targeted treatment. The goal is to see if the drug reduces joint swelling, pain, and inflammation over 24 weeks, follo…

This early-phase study tests a new drug called LY3484356 in 17 Chinese patients with a specific type of advanced breast cancer (ER+, HER2-). The main goal is to see how the drug moves through the body and how safe it is. Researchers will also check if the drug can shrink tumors. …

This study tests a once-daily pill called orforglipron to see if it can safely lower blood pressure in people who are overweight or have obesity. About 974 adults with high blood pressure and a BMI of 25 or higher will take either the study drug or a placebo. The goal is to find …

This study tests a once-weekly medicine called tirzepatide in adults with type 1 diabetes who are also overweight or obese. The goal is to see if it helps control blood sugar and reduce weight safely over about 20 months. Participants continue their insulin and are randomly assig…

This study tests whether galcanezumab, a monthly injection, can prevent chronic migraines in teenagers aged 12 to 17. About 312 teens with 15 or more headache days per month will receive either the drug or a placebo for 3 months. The goal is to see if the drug safely reduces the …

This study tests a new once-daily pill, orforglipron, to help adults with obesity or overweight who also have weight-related health issues like high blood pressure or sleep apnea. About 3,100 participants will take either the pill or a placebo for 72 weeks, with some continuing f…

This phase 2 study tests whether mazdutide, a drug originally developed for diabetes, can help people with alcohol use disorder drink less or stop drinking. About 300 adults with a current diagnosis will receive either mazdutide or a placebo for several weeks. The study tracks dr…

This study tests whether adding a weight-loss drug (tirzepatide) to a standard psoriasis treatment (ixekizumab) helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 250 adults will receive either ixekizumab alone or both drugs together for…

This study tests a once-weekly medicine called retatrutide in about 1000 adults with type 2 diabetes who are overweight or have obesity. The goal is to see if it helps with weight loss and, in a smaller group, improves sleep apnea. Participants receive either the drug or a placeb…

This program watches patients who get Zyprexa Relprevv, a long-acting shot for schizophrenia, to lower the chance of a rare side effect called post-injection delirium/sedation syndrome (PDSS). Up to 4,000 people will be followed to track how often PDSS happens and what might caus…

This study tests whether adding ramucirumab to the standard drug erlotinib helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 545 people who have not had treatment before will receive either the combination or erlotinib alone. The g…

This study tests whether two drugs—bimagrumab and tirzepatide—can help adults with obesity or overweight lose weight safely. About 252 participants will receive one or both drugs or a placebo for around 70 weeks. The main goal is to see how much body weight changes from the start…

This study tests different ways to increase the dose of the drug retatrutide to help people with obesity or overweight lose weight. About 600 participants without type 2 diabetes will take part for around 113 weeks. The main goal is to see how much weight they lose and how safe t…

This study tests whether a new drug, retatrutide, works better than the existing drug tirzepatide for weight loss in adults with obesity. About 800 participants will receive either drug for 89 weeks, and researchers will measure changes in body weight, BMI, and other health marke…

This study tests whether the targeted drug selpercatinib works better than standard chemotherapy for people with a rare type of advanced lung cancer (RET fusion-positive non-small cell lung cancer). About 261 participants will receive either selpercatinib or standard treatment. T…

This study tests a once-weekly injection called retatrutide in adults with type 2 diabetes and moderate to severe kidney disease whose blood sugar is not well controlled with insulin and other medications. About 320 participants will receive either retatrutide or a placebo for ar…

This study tested whether adding the drug abemaciclib to standard hormone therapy helps slow the growth of advanced breast cancer in postmenopausal women. About 463 women with hormone receptor-positive, HER2-negative breast cancer that had spread or returned took part. The main g…

This large Phase 3 study tests an injectable drug called lepodisiran in about 17,300 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease and stroke. Participants either already have heart disease or are at high risk for a first heart event. The goal…

This study tests two drugs, LY3841136 and tirzepatide, alone or together, to help adults with obesity or overweight and type 2 diabetes lose weight. About 350 participants will take the drugs or a placebo for up to 64 weeks. The goal is to see if these treatments are safe and eff…

This study tests an investigational drug called retatrutide in 643 adults with obesity. The goal is to see if it helps maintain weight loss over about 2.5 years. Participants first take the drug for 80 weeks, then are randomly assigned to continue the drug or switch to a placebo …

This study tests a drug called lebrikizumab in children aged 6 months to under 18 years with moderate-to-severe eczema. The goal is to see if it improves skin condition and reduces itching compared to a placebo. About 367 participants will receive either the drug or a placebo inj…

This study tests whether galcanezumab, a monthly injection, can prevent migraines in children and teens aged 6 to 17 with episodic migraine. Over 500 participants received either the drug or a placebo for 3 months. The goal is to see if the drug reduces the number of migraine day…

This phase 3 study tested whether adding the drug abemaciclib to standard hormone therapy (anastrozole or letrozole) helps postmenopausal women with a certain type of advanced breast cancer (HR+/HER2-). About 493 women who had not received prior treatment for their advanced disea…

This study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…

This study tests whether adding abemaciclib to fulvestrant can slow or stop the growth of a common type of advanced breast cancer (HR+, HER2-) that has worsened after initial treatment. About 368 participants will receive either the drug combo or a placebo plus fulvestrant. The g…

This study tests whether the drug ixekizumab is safe and effective for children with certain types of juvenile arthritis (enthesitis-related arthritis and juvenile psoriatic arthritis). About 101 children aged 2 to 17 years will receive either ixekizumab or the standard drug adal…

This large phase 3 study tests whether retatrutide can lower the risk of serious heart problems (like heart attacks and strokes) and slow kidney disease worsening in 10,000 adults with a BMI of 27 or higher who already have heart or kidney disease. Participants receive either ret…

This study looks at how well and how safely the drug mirikizumab works over the long term (up to 3 years) for people with moderate to severe ulcerative colitis. About 1,058 adults who were already in earlier studies will continue taking the drug. The goal is to see if it can keep…

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It includes 13 participants who already benefited from the drug in an earlier study and will continue treatment ever…

This study aimed to test a new drug called volenrelaxin in adults with chronic kidney disease to see if it could improve kidney function. Participants would have taken the drug or a placebo for about 24 weeks. However, the trial was withdrawn before enrolling anyone, so no result…

This study tests if tirzepatide, a once-weekly injection, can help adults with type 1 diabetes who are overweight or obese. About 905 participants will receive either tirzepatide or a placebo for up to 49 weeks. The goal is to see if the drug improves blood sugar control and help…

This study tests an oral drug called LOXO 292 in children with advanced solid or brain tumors that have a specific genetic change (RET alteration). The goal is to see if the drug can shrink tumors and control the disease. About 36 children whose cancer has not responded to standa…

This early-stage study tests a new medicine, LY3849891, in people with a type of fatty liver disease (MASLD) who have a specific gene change (PNPLA3 I148M). The main goal is to check the drug's safety and how the body processes it. Researchers will also use blood tests and liver …

This early-stage study tests an oral drug called LOXO-260 in people with certain cancers (like lung or thyroid cancer) that have a change in the RET gene and have stopped responding to other RET-targeted treatments. The main goals are to find the safest dose and check for side ef…

This study looks at the long-term safety and effectiveness of lebrikizumab for children aged 6 months to under 18 years with moderate-to-severe atopic dermatitis (eczema). About 310 participants who completed a prior study will receive lebrikizumab for up to 116 weeks. The goal i…

This study tests a once-daily pill called orforglipron against a placebo in 600 adults with obesity or overweight who also have type 2 diabetes. The goal is to see if the pill improves blood sugar levels and helps with weight loss over about 18 months. Participants must have a BM…

This early-phase study tests an oral drug called LY3410738 in people with advanced solid tumors that have specific IDH1 or IDH2 gene mutations. The goal is to find the best dose and see if it is safe and can shrink tumors. About 200 participants with bile duct cancer, cartilage c…

This study tests a drug called abemaciclib, given alone or with tamoxifen, in women with a certain type of advanced breast cancer (HR+, HER2-) that has worsened after previous treatments. The goal is to see if the combination helps keep the cancer from growing longer. About 234 w…

This study tests an experimental drug called LY3541860 in 63 adults with relapsing multiple sclerosis (MS). The goal is to see if it can safely reduce new areas of inflammation in the brain compared to a placebo. Participants will have MRI scans over about 9 months, with 6 months…

This study tests whether tirzepatide, a drug already used for diabetes and weight loss, can reduce the risk of serious heart problems and death in adults with obesity. Over 15,000 participants with a BMI of 27 or higher, and either existing heart disease or high risk factors, are…

This study tests a daily pill called baricitinib for children aged 2 to 18 with active uveitis (eye inflammation) linked to juvenile arthritis or a related condition. The goal is to see if it safely reduces eye inflammation better than current treatments. About 30 participants wh…

This study was designed to test two drugs, bimagrumab and tirzepatide, alone or together, for weight loss in adults who are overweight or obese and also have type 2 diabetes. The goal was to see how well they reduce body weight and improve health over about 13 months. However, th…

This study tests whether adding the drug abemaciclib to standard chemotherapy (temozolomide) helps children and young adults with a newly diagnosed high-grade glioma live longer without the cancer growing. About 45 participants who have completed radiation therapy will receive ei…

This study tests a new drug called imlunestrant against standard hormone therapy in 8,000 people with early-stage, hormone-sensitive breast cancer who have already had 2 to 5 years of hormone treatment and still have a higher risk of their cancer returning. The goal is to see if …

This study tested whether adding the drug abemaciclib to standard hormone therapy helps prevent breast cancer from coming back in people with a high-risk, early-stage type called HR+/HER2-. Over 5,600 participants who had surgery for node-positive breast cancer took either the co…

This study tests a drug called donanemab in people with early Alzheimer's disease. The goal is to see if it can slow down memory and thinking problems. About 1500 participants will receive the drug or a placebo for up to 93 weeks. The study is for people with mild symptoms and co…

This study tests a once-weekly injection called retatrutide to help people with obesity or overweight lose weight. About 250 adults who do not have diabetes will receive either the drug or a placebo for 65 weeks. The main goal is to see how much weight they lose and if the treatm…

This study tests whether donanemab, a monthly infusion, can delay or prevent memory and thinking problems in people who have early signs of Alzheimer's disease but no symptoms yet. About 3000 participants with a positive blood test for Alzheimer's-related proteins are being follo…

This study tests a new drug (LY3848575) to see if it safely reduces chronic nerve pain that starts in the feet and moves up the legs. About 558 adults with this type of pain will receive either the drug or a placebo for up to 30 weeks. The main goal is to measure changes in avera…

This early-stage study tests a new drug called LY3549492 in 120 healthy adults who are overweight or have obesity. The main goal is to check the drug's safety and how the body processes it over about 8 weeks. Participants receive multiple doses of the drug, and researchers monito…

This study tests whether the drug mevidalen can safely improve thinking, memory, and daily function in people with mild-to-moderate Alzheimer's disease. About 300 participants will receive either mevidalen or a placebo for 26 weeks. The main goal is to see if the drug eases sympt…

This study looks at whether lebrikizumab can help adults and teens with moderate eczema who have severe itching, even if only a small part of their body is affected. Participants receive the drug for 24 weeks and are monitored for up to 38 weeks. The main goal is to see if the tr…

This study looks at how long you need to fast and how stopping the diabetes/weight-loss drug tirzepatide changes the amount of food left in your stomach after a meal. Researchers will use ultrasound to check stomach contents in 40 people with type 2 diabetes or obesity. The goal …

This study tests a new drug called LY3981314 in healthy volunteers to see if it is safe and how the body handles it. About 76 healthy adults will receive a single injection under the skin and be monitored for up to 25 weeks. This is an early-stage study, so there is no direct tre…

This study looks at how well three different tablet versions of the drug LY4100511 are absorbed by the body in 48 healthy adults. It also checks if taking a common stomach acid medicine (a proton pump inhibitor) changes absorption. The goal is to find the best tablet form for fut…

This study follows 1,400 people with early-stage Alzheimer's disease or mild cognitive impairment to understand how much their care costs and how their health changes over time. Participants are not given any experimental treatment. The goal is to gather information that can help…

This early-stage study checks if the experimental drug LY4005130 is safe and how the body processes it. About 118 healthy adults will receive either the drug or a placebo, given as a shot under the skin or into a vein. The study does not aim to treat any disease; it simply gather…

This study looks at how long you need to fast and whether stopping the diabetes drug dulaglutide changes how much food stays in your stomach after a meal. About 20 people with type 2 diabetes will have their stomachs checked with ultrasound after eating. The goal is to better und…

This study tests a new drug called LY3537031 in 46 healthy adults. Researchers want to see how much of the drug gets into the blood and how fast the body removes it when injected under the skin in different spots or into a vein. The goal is to learn about the drug's behavior and …

This early-stage study tests a single dose of the experimental drug remternetug in 24 healthy Chinese adults. Researchers will check for side effects and measure how the drug moves through the body. The study lasts up to 25 weeks and does not aim to treat any disease.